Joan Mayol-Llinàs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joan Mayol-Llinàs has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Adam Nelson
Rosalind Franklin Institute, Harwell Campus, Didcot, Oxfordshire, OX11 0QX, UK.
3 shared publications Andrew Ayscough
Takeda Cambridge, Unit 418, Cambridge Science Park, Milton Road, Cambridge CB4 0PA, UK
1 shared publication- Fong Sang Lam
Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China
1 shared publication - Gang Li
Shenzhen Bay Laboratory
1 shared publication - Guixian Zhao
Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University, Chongqing 401331, P. R. China
1 shared publication - Hongzhe Sun
Department of Chemistry, The University of Hong Kong, Hong Kong SAR, P. R. China
1 shared publication
Latest Publications
- 7 February 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (4) , 543-555
Protein-templated ligand discovery via the selection of DNA-encoded dynamic libraries
DNA-encoded chemical libraries (DELs) have become a powerful technology platform in drug discovery. Dual-pharmacophore DELs display two sets of small molecules at the termini of DNA duplexes, thereby enabling the identification of synergistic binders against biological targets, and have been successfully applied in fragment-based ligand discovery and affinity maturation of known ligands. However, dual-pharmacophore DELs identify separate binders that require subsequent linking to obtain the full ligands, which is often challenging. Here we report a protein-templated DEL selection approach that can identify full ligand/inhibitor structures from DNA-encoded dynamic libraries (DEDLs) without the need for subsequent fragment linking. Our approach is based on dynamic DNA hybridization and target-templated in situ ligand synthesis, and it incorporates and encodes the linker structures in the library, along with the building blocks, to be sampled by the target protein. To demonstrate the performance of this method, 4.35-million- and 3.00-million-member DEDLs with different library architectures were prepared, and hit selection was achieved against four therapeutically relevant target proteins.
- 7 February 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (4) , 543-555
Protein-templated ligand discovery via the selection of DNA-encoded dynamic libraries
DNA-encoded chemical libraries (DELs) have become a powerful technology platform in drug discovery. Dual-pharmacophore DELs display two sets of small molecules at the termini of DNA duplexes, thereby enabling the identification of synergistic binders against biological targets, and have been successfully applied in fragment-based ligand discovery and affinity maturation of known ligands. However, dual-pharmacophore DELs identify separate binders that require subsequent linking to obtain the full ligands, which is often challenging. Here we report a protein-templated DEL selection approach that can identify full ligand/inhibitor structures from DNA-encoded dynamic libraries (DEDLs) without the need for subsequent fragment linking. Our approach is based on dynamic DNA hybridization and target-templated in situ ligand synthesis, and it incorporates and encodes the linker structures in the library, along with the building blocks, to be sampled by the target protein. To demonstrate the performance of this method, 4.35-million- and 3.00-million-member DEDLs with different library architectures were prepared, and hit selection was achieved against four therapeutically relevant target proteins.
- 22 March 2019
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 10 (4) , 616-620
Expansion of the structure–activity relationships of BACE1 inhibitors by harnessing diverse building blocks prepared using a unified synthetic approach
The structural diversity of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors was expanded by harnessing diverse building blocks that had been prepared via a unified lead-oriented synthetic approach. It was shown that the lipophilic cyclohexylmethyl group within a known series of BACE1 inhibitors could be productively replaced with a range of alternative ring systems.
- 22 March 2019
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 10 (4) , 616-620
Expansion of the structure–activity relationships of BACE1 inhibitors by harnessing diverse building blocks prepared using a unified synthetic approach
The structural diversity of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors was expanded by harnessing diverse building blocks that had been prepared via a unified lead-oriented synthetic approach. It was shown that the lipophilic cyclohexylmethyl group within a known series of BACE1 inhibitors could be productively replaced with a range of alternative ring systems.
- Open Access
- 3 November 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (91) , 12345-12348
Modular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery
A modular synthetic approach was developed that yielded thirty diverse lead-like scaffolds suitable for CNS drug discovery.
- 3 November 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (91) , 12345-12348
Open AccessModular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery
A modular synthetic approach was developed that yielded thirty diverse lead-like scaffolds suitable for CNS drug discovery.
- Open Access
- 1 July 2017
- Published by Elsevier in Drug Discovery Today
- Vol. 22 (7) , 965-969
Assessing molecular scaffolds for CNS drug discovery
- 1 July 2017
- Published by Elsevier in Drug Discovery Today
- Vol. 22 (7) , 965-969
Open AccessAssessing molecular scaffolds for CNS drug discovery